Key facts
- This page summarizes Michael Secora's Form 4 filing for Iambic Therapeutics, Inc. (IAM).
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 16 Oct 2026, 16:16.
Key filing fact
Ownership activity is grounded in SEC Form 4 disclosures.
Shares, units, or other non-derivative securities reported in this filing.
Award
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
Award
Additional SEC filing notes
Footnote F1
The reported shares are represented by restricted stock units, or RSUs, which vest as follows: 25% of the RSUs vest on September 10, 2027 and the remaining RSUs vest in twelve equal quarterly installments beginning on December 10, 2027.
Footnote F2
Twenty-five percent of the shares subject to the option vest on October 14, 2027 and 1/48th of the shares vest monthly thereafter.